Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Jay Tuttle
A First-In-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination With Erlotinib in Advanced Cancer
Clinical Cancer Research
Cancer Research
Oncology
Related publications
A Phase I First-In-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients With Advanced Cancer
Clinical Cancer Research
Cancer Research
Oncology
A Phase I Trial Investigating Pulsatile Erlotinib in Combination With Gemcitabine and Oxaliplatin in Advanced Biliary Tract Cancers
Investigational New Drugs
Oncology
Pharmacology
Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
A Phase I Dose‐Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination With Erlotinib in Patients With Advanced Solid Tumors
Oncologist
Cancer Research
Medicine
Oncology
Erratum To: A Phase I Dose-Escalation Study of Selumetinib in Combination With Erlotinib or Temsirolimus in Patients With Advanced Solid Tumors
Investigational New Drugs
Oncology
Pharmacology
A Phase I First-In-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients With Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
A Phase I Trial of Combination Trastuzumab, Lapatinib, and Bevacizumab in Patients With Advanced Cancer
Investigational New Drugs
Oncology
Pharmacology
A Phase I Study of Weekly Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies
Oncologist
Cancer Research
Medicine
Oncology
First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
